Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biotech firms Celltrion and Aprogen are racing to bring biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Japan